Medical need not market behind Takeda's Japan fomepizole deal
This article was originally published in Scrip
Executive Summary
Takeda is to exclusively develop and market in Japan Paladin Labs' product for ethylene glycol and methanol poisoning fomepizole as part of a government-driven commitment to commercialise high-need but unapproved products in the country.